{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:55:37Z","timestamp":1781520937798,"version":"3.54.1"},"reference-count":10,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Soc. Bras. Med. Trop."],"abstract":"<jats:p>ABSTRACT  Background:  A national dengue vaccination campaign using TAK-003 was launched in 2024, targeting adolescents. Post-licensure surveillance suggested higher-than-expected hypersensitivity reactions.  Methods:  We conducted a descriptive study using vaccine adverse event data and vaccination records from Belo Horizonte among individuals aged 6-14 years.  Results:  Of the 146,115 doses administered, 28 hypersensitivity reactions were reported (191.6 per million), including nine cases of anaphylaxis and two of anaphylactic shock. All events followed the first dose. Mean age was 9.4 years, and mean time to symptom onset was 31 minutes.  Conclusions:  Hypersensitivity rates exceeded expected vaccine-associated levels, reinforcing the need for continued pharmacovigilance.<\/jats:p>","DOI":"10.1590\/0037-8682-0198-2026","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:35:20Z","timestamp":1781519720000},"source":"Crossref","is-referenced-by-count":0,"title":["Hypersensitivity reactions to dengue vaccine TAK-003 (Qdenga\u00ae) following an immunization campaign targeting children and adolescents"],"prefix":"10.1590","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2041-0480","authenticated-orcid":false,"given":"M\u00e1rcia Paulliny Soares","family":"Bahia","sequence":"first","affiliation":[{"name":"Prefeitura de Belo Horizonte,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-8173","authenticated-orcid":false,"given":"Silon de Souza","family":"Gomes Junior","sequence":"additional","affiliation":[{"name":"Hospital Eduardo de Menezes,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1530-9284","authenticated-orcid":false,"given":"Argus Le\u00e3o","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Prefeitura de Belo Horizonte,  Brasil; Hospital Eduardo de Menezes,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-3677","authenticated-orcid":false,"given":"Hoberdan Oliveira","family":"Pereira","sequence":"additional","affiliation":[{"name":"Prefeitura de Belo Horizonte,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1845-8493","authenticated-orcid":false,"given":"Jos\u00e9 Geraldo Leite","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias M\u00e9dicas de Minas Gerais,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-5425","authenticated-orcid":false,"given":"Alexandre Sampaio","family":"Moura","sequence":"additional","affiliation":[{"name":"Prefeitura de Belo Horizonte,  Brasil; Hospital Eduardo de Menezes,  Brasil; Faculdade de Sa\u00fade Santa Casa de Belo Horizonte,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","series-title":"Informe t\u00e9cnico-operacional: estrat\u00e9gia de vacina\u00e7\u00e3o contra a dengue - 2024","year":"2024"},{"issue":"21","key":"ref2","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal S","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera L","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou V","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/vaccines12070770","article-title":"Immunogenicity, safety and efficacy of the dengue vaccine TAK-003: a meta-analysis","volume":"12","author":"Flacco ME","year":"2024","journal-title":"Vaccines"},{"issue":"26","key":"ref6","doi-asserted-by":"crossref","first-page":"126407","DOI":"10.1016\/j.vaccine.2024.126407","article-title":"Safety signal detected: anaphylaxis after attenuated dengue vaccine (TAK-003) - Brazil, March 1, 2023-March 11, 2024","volume":"42","author":"Percio J","year":"2024","journal-title":"Vaccine"},{"issue":"15","key":"ref7","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2022.11.027","article-title":"Anaphylaxis: revision of the Brighton Collaboration case definition","volume":"41","author":"Gold MS","year":"2023","journal-title":"Vaccine"},{"key":"ref8","series-title":"Nota T\u00e9cnica 14\/2025-CGFAM\/DPNI\/SVSA\/MS - Atualiza\u00e7\u00e3o sobre as orienta\u00e7\u00f5es para identifica\u00e7\u00e3o, investiga\u00e7\u00e3o e manejo da anafilaxia e outras rea\u00e7\u00f5es de hipersensibilidade supostamente atribu\u00edveis \u00e0 vacina\u00e7\u00e3o ou imuniza\u00e7\u00e3o pela vacina dengue tetravalente (atenuada)","year":"2025"},{"issue":"11","key":"ref9","article-title":"Adverse Events and Immunization Errors Following a Mass Immunization Campaign with TAK-003 in Dourados, Brazil: A Post-Marketing Safety Surveillance Analysis","volume":"97","author":"Anschau LCK","year":"2025","journal-title":"J Med Virol"},{"key":"ref10","first-page":"100749","article-title":"Retrospective analysis of one year of passive safety surveillance data following implementation of the dengue vaccine, Qdenga\u00ae (TAK-003), at private vaccination centers, in Buenos Aires, Argentina","volume":"27","author":"Castellano VE","year":"2025","journal-title":"Vaccine"}],"container-title":["Revista da Sociedade Brasileira de Medicina Tropical"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0037-86822026000101407&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:35:22Z","timestamp":1781519722000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0037-86822026000101407&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":10,"alternative-id":["S0037-86822026000101407"],"URL":"https:\/\/doi.org\/10.1590\/0037-8682-0198-2026","relation":{},"ISSN":["1678-9849","0037-8682"],"issn-type":[{"value":"1678-9849","type":"electronic"},{"value":"0037-8682","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e0198-2026"}}